Teriparatide is indicated for use in postmenopausal women with osteoporosis at a high risk for fracture or with a history of ostoporotic fracture, patients with multiple risk factors for fracture, and for patients who have failed or are intolerant to other available osteoporosis therapy.

Teriparatide is also indicated to increase bone mass in men with primary or hypogonadal osteoporosis at high risk of fracture, patients with multiple risk factors for fracture, and for patients who have failed or are intolerant to other available osteoporosis therapy.

Teriparatide is indicated as well for the treatment of men and women with osteoporosis associated with sustained systemic glucocorticoid therapy.

Teriparatide should not be prescribed for patients who are at increased risks for osteosarcoma. This includes those with Paget's Disease of bone or unexplained elevations of serum alkaline phosphate, open epiphysis, or prior radiation therapy involving the skeleton.

Purity (HPLC): 95.0%min.
Appearance: White powder
Single Impurity (HPLC): 2.0%max
Amino Acid Composition: ±10% of theoretical
Peptide Content (N%): ≥80.0%
Water Content (Karl Fischer): ≤10.0%
Acetate Content (HPIC): ≤15.0%
MS (ESI): Consistent
Mass Balance: 95.0~105.0%

Pharmaceutical Peptides   52232-67-4, Buy Teriparatide Powder, China Teriparatide Powder, Steroids Raw Powder, Teriparatide Dosage, Teriparatide Injection, Teriparatide Peptide, Teriparatide Powder, Teriparatide Price, Teriparatide Raw, Teriparatide Raw Powder, Teriparatide Source, Teriparatide Supplier, Teriparatide Usage, Teriparatide Vials